Executive Summary

The Japanese market for biopsy devices occupies a unique space formed by three structural factors that cannot be reversed: an ancient and heavily burdened population when it comes to cancer cases, a healthcare system that emphasizes early diagnosis more than anywhere else, and a domestic medical technology sector led by internationally renowned brands such as Olympus and FUJIFILM, which are incorporating artificial intelligence, robots, and liquid biopsy techniques into their products.

The valuation of the Japanese biopsy devices market in 2024 was somewhere between $127 million and $144 million, with the market forecast to double or even triple by 2033, at a CAGR of 7%–10%. Japan may not just be one of the fastest-growing Asian-Pacific countries when it comes to biopsy devices, it can also be considered a harbinger of innovations, including new products from companies such as Olympus, such as the SecureFlex fine-needle biopsy device.

Market Overview & Definition

Biopsy devices are medical devices employed to obtain biopsy samples from the body, either in liquid form or as solid tissue samples for laboratory testing, mainly for cancer diagnosis and identification of infections and inflammation. Biopsy devices range from core needle biopsy guns, fine needle aspiration (FNA) devices, vacuum-assisted biopsy (VAB) devices, biopsy forceps, endoscopic biopsy devices, and increasingly advanced liquid biopsy devices, which detect circulating tumor DNA (ctDNA) in the blood without any need for sampling.

Japan is among the most biopsy-procedural countries within the Asia-Pacific region. This is due to the use of biopsy devices in diagnosing the five primary cancers screened for under Japan's national cancer control program, namely gastric cancer, colorectal cancer, lung cancer, breast cancer, and cervical cancer. The Japanese health system features a very comprehensive network of hospitals, national health insurance, and a doctor-centric diagnostic practice culture. This makes Japan one of the leading countries in the region with regards to biopsy procedures.

Market Size & Growth Data

The estimates of Japan’s market for biopsy devices differ based on the scope used for estimation, yet there is a consensus on its growth direction. Japan holds the position of being among the top growing biopsy devices markets in the Asia-Pacific region ahead of competitors such as Australia and South Korea in terms of adoption intensity. For instance, the global market for biopsy devices stood at about $7.52 billion in 2024 (based on methodology) and was expected to rise to $24.47 billion by 2033 at CAGR of 14%.

The Oncology Imperative: Why Japan's Cancer Burden Drives This Market

There is no single more critical determinant of the biopsy devices market in Japan than its cancer epidemiology. In 2020 alone, 950,000 cases of cancer were reported in Japan, according to the data from its National Cancer Registry. Furthermore, as people get older, this number continues to rise. As per the figures published by GLOBOCAN 2022, the five most prevalent cancers in Japan are colorectal (145,756 cases or 14.5% share), lung (136,723, 13.6%), stomach (126,724, 12.6%), prostate (104,318, 10.4%), and breast (91,916, 9.1%) cancers.

All of these are extremely dependent on biopsies. For example, colorectal cancer detection through colonoscopy, Japanese leadership in performing gastric endoscopies, increasing numbers of breast cancer cases among females, are just some of the many examples that directly translate into procedure volumes for manufacturers of biopsy devices.

This demographic trend is amplified in Japan by the fact that 28% of its residents are aged 65 or above (the highest percentage of all countries globally). Moreover, cancer rates increase significantly once people reach this age group.

Key Growth Drivers

1. Cancer Cases & Country-wide Biopsy Programs: The national cancer screening programs run in Japan under mandate from the country's Ministry of Health, Labour, and Welfare result in an annual volume of biopsy procedures. Among these is one for stomach cancer that entails endoscopy or upper Gastrointestinal Imaging of all individuals who are aged 50 years and above every two years. Likewise, there is the biennial fecal test for colorectal cancer for those aged 40 years and above, which results in colonoscopy and biopsy procedures.

2. Increased Prevalence of Minimally Invasive Techniques: The Japanese patient population is known for the desire to perform minimally invasive procedures that reduce pain and facilitate speedy recovery, a characteristic that makes them a perfect market for vacuum-aided and image guided biopsy techniques in the market today.

3. Expansion of Liquid Biopsy & Precision Medicine: Liquid biopsy, where the ctDNA in the patient’s bloodstream is analyzed instead of using tissue biopsies, has been gaining more traction within the Japanese government’s push for genomic medicine. The approval by MHLW of the Guardant360® CDx liquid biopsy test to serve as a companion diagnostic tool for the treatment of breast cancer became Japan’s first-ever approval of a companion diagnostic that uses blood-based testing for detecting ESR1 mutations. This happened in October 2025, when Guardant Health Japan obtained the approval for their product.

4. Integration of AI and Robotics: In terms of the convergence of AI assisted imaging and biopsy procedures, a new level of high value device technology is emerging. For instance, the new release of ColonPRO by Medtronic, in April 2024, for use with the company's GI Genius™ AI assisted endoscopy system increases colorectal polyp detection and provides accurate information for future biopsies. Furthermore, the Monarch bronchoscopy system, a robotics assist device for navigating the lungs to perform biopsy, made it to Japan from Johnson & Johnson MedTech, in June 2025. Clearly, these are not just product enhancements; they mark a fundamental change towards procedure intelligence.

5. NHI Coverage for Image-Guided and Minimally Invasive Biopsy Techniques:  As indicated earlier, NHI coverage for image-guided core needle biopsy technologies is gradually becoming inclusive. By January 2026, for example, the process had been extended further to increase coverage of the minimally invasive biopsy technique.

Market Restraints & Challenges

The biopsy device market in Japan does not lack its own challenges. The prohibitive cost of cutting-edge biopsy systems, especially robotic-assisted and artificial intelligence-enabled devices, makes these devices challenging to adopt at regional hospitals and clinics in less densely populated cities outside Tokyo, Osaka, and Nagoya. With a cost-effective focus in the Japanese healthcare system, the pricing review by NHI is a potential hurdle for higher-cost imported devices.

Another hurdle relates to the limited workforce. Japan experiences a shortage of skilled endoscopists and radiologists, particularly in rural prefectures, which impacts the rate of procedures and subsequently the consumption of biopsy devices. In addition, the path to regulatory approval with MHLW's Pharmaceuticals and Medical Devices Agency (PMDA) remains stringent despite improved turnaround times.

Finally, the conflict between tissue and liquid biopsy platforms is arising. The emergence of liquid biopsy platforms that are now gaining coverage raises the issue of structural replacement for tissue-based devices, especially in monitoring and follow-up use cases. Under the current MHLW policy in Japan, liquid biopsy can be used when tissue biopsy becomes technically challenging; however, this limit is expected to change.

Technology & Innovation Landscape

The innovation ecosystem for biopsies in Japan is characterized by three interlocking factors. The first factor is disposability, where biopsies transition from being reusable to single-use. This eliminates the risk of cross-contamination and corresponds to the strict hygiene culture at Japanese hospitals. Olympus introduced SecureFlex, a single-use fine needle biopsy instrument, in October 2025. It targeted Japan and Europe before releasing it globally. It is a clear indication that Japan can serve as a launch reference market for high-end medical technology products.

The second factor is the use of AI in the targeting of needle biopsy. AI systems analyze live imaging data to ensure that the needle lands directly on the lesion area to eliminate sampling errors. In August 2024, Hitachi High-Tech Corporation partnered with Gencurix. They aim at developing cancer molecular diagnostic tests through the use of genomic data.

Thirdly, there has been an expansion of liquid biopsy applications. The Japanese C-CAT database, which is one of the world’s largest cancer genomics registries, is speeding up the study of ctDNA markers and laying down the foundation for reimbursement of liquid biopsies under NHI coverage. By mid-2022, there have already been more than 233 cancer genome medical institutes established across the country.

Competitive Landscape

Japan's biopsy devices market is served by a mix of dominant domestic medtech companies and established global players.

Olympus Corporation is the most strategically important domestic player, holding a commanding position in endoscopic biopsy tools globally and in Japan specifically. Its October 2025 SecureFlex launch, prioritizing Japan as a first commercial market, underscores its home-market commitment. Olympus's endoscopy platform dominates Japan's gastrointestinal biopsy segment.

FUJIFILM Corporation is a significant domestic competitor in endoscopic imaging and biopsy guidance systems, leveraging its deep roots in imaging technology and its growing healthcare division.

Hologic Inc. leads the breast biopsy segment in Japan with its Brevera Breast Biopsy System (featuring CorLumina Imaging Technology), launched specifically for the Japanese market, and the Mammotome AutoCore Single Insertion Core Biopsy System (November 2025). Hologic's women's health focus positions it well given Japan's rising breast cancer incidence.

Boston Scientific Corporation and Medtronic are key participants across gastrointestinal and pulmonary biopsy segments, with Medtronic's AI-powered GI Genius/ColonPRO platform gaining traction in colorectal biopsy guidance. Johnson & Johnson MedTech's Monarch robotic bronchoscopy system entered Japan's lung biopsy market in 2025.

Guardant Health Japan has established itself as the leading liquid biopsy platform, with multiple MHLW approvals for Guardant360® CDx across tumor types. HaploX, a transomics liquid biopsy specialist, established a Japanese subsidiary in March 2024 to expand its services.

Domestic niche players include Taisho Biomed Instruments and Dr. Japan Co., serving the local market with Japan-specific product configurations.

Recent Developments in Biopsy Devices Market (2024–2026)

• October 2025: Olympus launched SecureFlex, a single-use fine needle biopsy device, with Japan as a priority market, targeting endoscopic ultrasound (EUS)-guided procedures.
• October 2025: Guardant Health Japan received MHLW approval for Guardant360® CDx as a companion diagnostic for ESR1 mutation detection in breast cancer — Japan's first blood-based CDx for this indication.
• November 2025: Mammotome (Devicor) launched the AutoCore Single Insertion Core Biopsy System, the first automated spring-loaded core needle device, targeting breast biopsy efficiency.
• June 2025: Johnson & Johnson MedTech's Monarch robotic bronchoscopy system expanded in Japan, offering minimally invasive deep-lung biopsy with high diagnostic yield.
• January 2026: NHI expanded reimbursement coverage for image-guided core needle biopsy techniques at specialized centers, accelerating adoption.
• February 2026: Next-generation disposable biopsy instruments with real-time position sensors gained traction in Japan, aligned with Japan's procedural precision standards.
• August 2024: Hitachi High-Tech Corporation entered a strategic partnership with Gencurix in cancer molecular diagnostics, signaling the convergence of hardware and genomic intelligence.
• March 2024: HaploX established a Japanese subsidiary to expand liquid biopsy and transomics analysis services, marking a push by a China-based genomics firm into Japan's precision oncology ecosystem.

Japanese Business Culture & Market Nuances

A thorough understanding of the Japanese market for biopsy devices necessitates an understanding of the nature of procurement processes in the Japanese hospitals. The purchasing process, especially regarding large-scale purchases such as robotic biopsy machines, involves deliberation in committees and takes up to 12–24 months to complete. This is based on the concept of "nemawashi," whereby a decision cannot be made without first gaining consensus among departmental heads, procurement officers, and hospital administrators.

This means that the medical evidence supporting the need for such devices needs to be provided via the Japanese academic community to prove its value. For instance, the publication of evidence regarding benefits of a biopsy device in the Japanese medical journals, together with recommendations from the key opinion leaders in Japan's National Cancer Center Hospital and University of Tokyo Hospital will be fundamental for success.

There are high expectations regarding the quality in Japan. The Japanese physicians have extremely high expectations regarding the precision and consistency of biopsies. The expectation is tied to the general monozukuri concept prevalent in Japan. It only takes one performance problem in the field for the company to get bad reviews.

Moreover, there is an increasing preference among the Japanese for single-use, sterile devices because of Japan's highly effective infection control policies in hospitals. This structural advantage helps the firms that produce such products as they attract a premium price. Olympus recently introduced its SecureFlex to cater to this preference.

Any firm that wants to enter the Japan market for biopsies must prepare for heavy spending on Japanese language marketing material, regulatory team, and partnerships with distributors.

Regulatory & Policy Environment

The major regulatory authority for biopsy devices in Japan is the Pharmaceuticals and Medical Devices Agency (PMDA), functioning as a part of MHLW. Medical devices are categorized into Class I-IV within the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, extensively updated in 2014. Biopsy devices belong to Classes II/III and require clinical and quality system reviews.

International regulations have been harmonized with Japanese ones quite well, as the ISO 13485 standard is applicable for the quality management of medical devices in Japan, while IEC 62304 relates to medical device software. The Sakigake program is the designation for innovative medical devices in Japan, similar to FDA Breakthrough Devices Designation. It helps to speed up the approval process up to 6-12 months, and some genomic diagnostic systems have been designated.

Liquid biopsies are regulated through NHI reimbursement guidelines for CGP testing in designated Cancer Genome Medical Institutes. The priority is given to tissue biopsy for CGP, whereas liquid biopsy is used as an alternative method only if the tissue biopsy cannot be conducted.

Under the Cancer Registration and Statistics Act (2016), hospitals were made to report all cancer patients, thus making the country’s cancer registry (C-CAT) among the best in the world. This information is being used to speed up evidence-based reimbursement of biopsies.

Global Comparison & Japan's Position

Japan holds a distinctive position in the global biopsy devices landscape. While North America dominates global biopsy device revenue (approximately 42.5% share in 2024), and Europe leads in liquid biopsy clinical integration, Japan is consistently cited as Asia-Pacific's fastest-growing biopsy device market — driven by its combination of high cancer burden, high diagnostic intensity, and advanced healthcare infrastructure.

Japan's gastric biopsy volume is globally unmatched: stomach cancer screening via endoscopy at national scale generates a baseline of biopsy procedures that no other country replicates. Japan's endoscopy penetration rate, its world-leading colonoscopy volumes, and the density of hospital-based cancer screening all create a procedural intensity that sustains device demand at levels disproportionate to Japan's population size.

Where Japan lags relative to the US is in the commercialization speed of emerging platforms — liquid biopsy, robotic biopsy systems, and AI-guided tools tend to enter the US market first, with Japan following 12–24 months later due to PMDA review timelines. However, once a platform clears Japanese regulatory hurdles and gains NHI reimbursement, adoption tends to be rapid and sustained.

Integration of AI and robotics in the guidance of procedures will increase both the profitability of every biopsy procedure performed and the cost incurred per device deployed. As such, there will be a market environment where fewer devices will be sold, with more of an emphasis on high-end med-tech brands with good clinical partnerships.

There will be even greater personalization of treatment in cancer therapy. As drugs targeting certain types of cancer become available, there will have to be biopsy device approvals to go alongside them.

Case Studies

Case Study 1: Olympus Launches SecureFlex in Japan First (2025): When Olympus chose Japan and Europe, rather than the US — as the first commercial markets for SecureFlex, its new single-use fine needle biopsy device, it was a deliberate strategic signal. Japan's demand for disposable precision instruments, its dense network of endoscopy centers, and Olympus's existing clinical relationships made it the ideal launch reference market. The move illustrates how a Japanese company can leverage its home market as a global proving ground.

Case Study 2: Guardant Health Japan's Liquid Biopsy Regulatory Journey: Guardant360® CDx received its first MHLW approval in March 2022 for comprehensive genomic profiling in advanced solid tumors. By October 2025, it had accumulated multiple companion diagnostic approvals across different cancer types, with NHI reimbursement available at designated institutions. The company's systematic regulatory strategy, one approval at a time, building clinical evidence at C-CAT institutions, is a model for how foreign liquid biopsy companies can build credibility within Japan's consensus-driven healthcare system.

Case Study 3: Japan's C-CAT as a Market Infrastructure Asset: The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) is one of the world's most ambitious cancer genomic data infrastructures. With over 7,400 patient CGP records analyzed and growing, C-CAT is generating real-world evidence on liquid biopsy clinical utility in Japan's specific patient population. For biopsy device companies, C-CAT represents both a clinical validation engine and a regulatory runway, published C-CAT data directly informs MHLW reimbursement decisions.

Conclusion

The Japanese biopsy device market represents an attractive and structurally driven market opportunity based on the demographics, the health care system designed for early cancer detection, and the innovative medical technology companies in the country pioneering disposable, robotic and AI-enabled and liquid biopsy devices. The market is forecasted to increase two times over the next 10 years due to increasing NHI coverage, shift towards liquid biopsy and procedural advancements through robots. Japan also provides foreign companies not only with commercial opportunities but also, as shown with the case of Olympus' SecureFlex, some of the most reliable environments for proving the clinical validity of their products.

FAQs:

1. What is the size of Japan's biopsy devices market?

Ans: Japan's biopsy devices market was valued between $127 million and $144 million in 2024, depending on the scope of analysis. It is forecast to reach $244 million to $414 million by 2033–2035, growing at a CAGR of approximately 7–10%.

2. Which companies lead the Japan biopsy devices market?

Ans: Key players include Olympus Corporation and FUJIFILM Corporation (dominant in endoscopic biopsy tools), Hologic (breast biopsy systems), Boston Scientific, Medtronic, Johnson & Johnson MedTech, Guardant Health Japan (liquid biopsy), and Taisho Biomed Instruments (domestic niche).

3. What are the main drivers of growth?

Ans: Japan's aging population, high cancer incidence (950,000+ new cases annually), national cancer screening programs, NHI reimbursement expansion for image-guided and genomic biopsy, and the rapid adoption of liquid biopsy and AI-assisted guidance systems are the primary growth drivers.

4. How does Japan compare globally in biopsy devices?

Ans: Japan is Asia-Pacific's fastest-growing biopsy device market and globally unique in its gastric and colorectal biopsy volumes, driven by world-leading endoscopy screening rates. North America holds the largest global market share (~42.5%), but Japan leads Asia-Pacific in procedural intensity and device adoption sophistication.

5. What is liquid biopsy's status in Japan?

Ans: MHLW has approved multiple liquid biopsy platforms under NHI for comprehensive genomic profiling at designated cancer genome medical institutions. Currently, liquid biopsy is approved as a secondary option when tissue biopsy is not feasible — a framework expected to broaden as clinical evidence accumulates through Japan's C-CAT registry.

6. What regulatory body governs biopsy devices in Japan?

Ans: The Pharmaceuticals and Medical Devices Agency (PMDA), under the Ministry of Health, Labour and Welfare (MHLW), governs all medical device approvals in Japan under the PMD Act.